7 days
Test Updated:
Anti-NXP2
NXP-2 (P140)
Looking to order a test?
We’ve provided helpful links to make ordering easy.
Find a RequisitionAll specimens should be accompanied by a requisition.
Submitting SpecimensLearn about how to properly label and where to ship specimens.
Order Kits and SuppliesMLabs provides all the supplies necessary for the collection of specimens.
Test FAQVisit our provider FAQ and learn about common questions to ordering tests.
Test Overview
EIA
Anti-NXP-2 antibodies are present in 1.6-30% of adult DM and 18-25% of JDM. In JDM they are associated with cutaneous calcinosis cutis. In adult DM they are significantly associated with the presence of cancer (cancer was found in 13.6% of Anti-NXP-2 positive DM patients). Anti-MDA5 antibodies are present in 7-35% of adult DM. Features consist of absent or mild muscle symptoms (CADM); associated with rapidly progressive ILD; specific mucocutaneous features of skin ulcerations and papules; higher risk of oral ulcerations and arthritis.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.